Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on Molecular Biology, Diagnosis, and Therapy
Open Access
- 1 October 2014
- journal article
- research article
- Published by SAGE Publications in Cancer Control
- Vol. 21 (4), 279-289
- https://doi.org/10.1177/107327481402100404
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. Most patients with BPDCN have skin lesions and simultaneous involvement of the peripheral blood, bone marrow, and lymph nodes. A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4+CD56+ hematodermic neoplasm, and blastic natural killer cell lymphoma. Data regarding diagnosis, prognosis, and treatment were analyzed. BPDCN is derived from precursor plasmacytoid dendritic cells. The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4, CD56, CD123, blood dendritic cell antigens 2 and 4, and CD2AP markers. Multiple chromosomal abnormalities and gene mutations previously reported in patients with myeloid and selected lymphoid neoplasms were identified in approximately 60% of patients with BPDCN. Prospectively controlled studies to guide treatment decisions are lacking. The overall response rate with aggressive acute lymphoblastic leukemia-type induction regimens was as high as 90%, but the durability of response was short. Median survival rates ranged between 12 and 16 months. Patients with relapsed disease may respond to L-asparaginase-containing regimens. Allogeneic hematopoietic stem cell transplantation, particularly when performed during the first remission, may produce durable remissions in selected adults. BPDCN is a rare aggressive disease that typically affects elderly patients. The most commonly affected nonhematopoietic organ is the skin. Although BPDCN is initially sensitive to conventional chemotherapy regimens, this response is relatively short and long-term prognosis is poor. In the near future, novel targeted therapies may improve outcomes for patients with BPDCN.This publication has 62 references indexed in Scilit:
- Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow TransplantationBlood, 2013
- Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasmBone Marrow Transplantation, 2012
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyHaematologica, 2012
- Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell NeoplasmClinical Cancer Research, 2011
- Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning IntensityTransplantation and Cellular Therapy, 2011
- Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implicationsHaematologica, 2010
- Novel markers of normal and neoplastic human plasmacytoid dendritic cellsBlood, 2008
- Natural killer cell neoplasmsCancer, 2008
- Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon‐α via toll‐like receptor 9Clinical and Experimental Allergy, 2008
- CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of CancerJournal of Clinical Pathology, 2006